Merck Closes In on $6B Biotech Acquisition to Supercharge Its Cancer Drug Pipeline
Terns Pharma stock has jumped since promising clinical data on its bone and blood cancer treatment last year
Merck nears $6bn biotech deal to boost cancer drug pipeline
Pharmaceutical giant Merck is in advanced talks to acquire Terns Pharmaceuticals in a deal valued at approximately $6 billion, according to sources familiar with the matter. The acquisition would significantly bolster Merck's oncology pipeline as the company seeks to diversify its portfolio ahead of looming patent expirations on some of its best-selling drugs. The deal, which could be announced in the coming days, represents one of the largest biotech acquisitions so far this year.
Terns Pharmaceuticals has attracted significant investor attention since releasing promising clinical data on its experimental treatment for bone and blood cancers last year. The company's stock price has surged on the back of those results, which demonstrated strong efficacy and a favorable safety profile in early-stage trials. Analysts have pointed to the treatment's potential to address unmet medical needs in hematological malignancies, a rapidly growing area of oncology research that has drawn intense competition among major drugmakers.
For Merck, the deal would come at a critical time as the company faces the eventual loss of patent protection on Keytruda, its blockbuster immunotherapy that generates tens of billions of dollars in annual revenue. The company has been actively pursuing acquisitions and licensing agreements to build out its cancer drug portfolio and secure future growth. Industry observers have noted that Merck has been particularly aggressive in targeting mid-stage biotech firms with differentiated therapeutic approaches that could complement its existing oncology franchise.
Neither Merck nor Terns Pharmaceuticals has officially commented on the negotiations, and sources caution that talks could still fall apart before a final agreement is reached. If completed, the transaction would add to a wave of dealmaking activity in the pharmaceutical sector, where large companies have increasingly turned to acquisitions to replenish their pipelines. Wall Street analysts expect further consolidation in the biotech space as promising clinical-stage companies continue to attract the attention of deep-pocketed buyers looking to secure the next generation of cancer therapies.